论文部分内容阅读
目的:观察沙美特罗替卡松粉吸入剂预防急性高原反应的效果。方法:55名青年随机分为沙美特罗组(n=31)和安慰剂组(n=24),自海拔1400m历时4天进入5200m,第2天开始,沙美特罗组每天早晚各吸入沙美特罗替卡松粉一个剂量(沙美特罗50μg,丙酸氟替卡松100μg),连续7天;安慰剂组用同样方法吸入少量生理盐水。以军用卫生标准GJB1098-91《急性高原反应的诊断和处理原则》随访观察第2天、4天、7天急性高原反应的严重程度、SaO2和脉率。结果:进入海拔5200m第7天安慰剂组急性高原反应症状较沙美特罗组严重(P<0.05),第2天、4天安慰剂组脉率较沙美特罗组减慢(P<0.05),SaO2两组无显著性意义(P>0.05)。随访期间沙美特罗组发生一例高原脑水肿,安慰剂组发生一例高原肺水肿。结论:沙美特罗替卡松粉吸入剂预防急性高原反应无确切效果。
Objective: To observe the effect of salmeterol and fluticasone powder inhaler in preventing acute altitude sickness. Methods: Fifty-five youths were randomly divided into salmeterol group (n = 31) and placebo group (n = 24). After advancing from 1400m altitude to 5200m for 4 days, from the second day, One dose of salmeterol (50 μg of salmeterol and 100 μg of fluticasone propionate) was administered for 7 consecutive days; placebo received a small amount of saline in the same manner. The military health standards GJB1098-91 “principles of diagnosis and treatment of acute altitude sickness” follow-up observation day 2, 4, 7 days the severity of acute altitude sickness, SaO2 and pulse rate. Results: Compared with salmeterol group, the incidence of acute altitude sickness in placebo group on day 7 at 5200 m altitude was significantly worse than that of salmeterol (P <0.05), and the pulse rate of placebo group on day 2 and 4 was slower than salmeterol group (P <0.05) , SaO2 two groups had no significant (P> 0.05). One case of high altitude brain edema occurred in the salmeterol group and one case of high altitude pulmonary edema in the placebo group during follow-up. Conclusions: Salmeterol ticagamme inhaled powder has no specific effect in preventing acute altitude sickness.